Before-and-After Ad Rules in Malaysia (2026)

Which rulebook does my before-and-after ad fall under?

Before you argue about the creative, sort the ad into a bucket. Malaysia has three, and they carry completely different obligations.

Bucket one: a cosmetic claim about a cosmetic product. Nobody approves this in advance. NPRA runs a self-regulation regime and you carry the liability. The rules you must satisfy live in Annex I Part 8 (claims) and Annex I Part 10 (advertisement) of the Guidelines for Control of Cosmetic Products in Malaysia.

Bucket two: a medicinal claim about a product. Section 4B(1) of the Medicines (Advertisement and Sale) Act 1956, Act 290, says no person shall publish an advertisement for the use of any article as a medicine, an appliance or a remedy for the treatment or prevention of diseases or conditions of human beings other than those specified in section 3(1) of the same Act, unless the advertisement has been approved by the Medicine Advertisements Board. Prior approval, by statute, before publication. Hold on to that carve-out, because the conditions section 3(1) does specify are the ones with no approval route at all, and we come back to them below.

Bucket three: a clinic advertising a skill or service. Section 4A of the same Act bans publishing any advertisement that refers to a skill or service for the treatment, prevention or diagnosis of any ailment, disease, injury, infirmity or condition affecting the human body and is capable of inducing, or contains an express or implied invitation to, a person to seek the advertiser's advice. Its proviso carves out two routes and only two: publication with the Minister's approval by a professional body of the medical or an allied profession established or registered under written law, and publication with Medicine Advertisements Board approval by a private hospital, private clinic, private radiological clinic or private medical laboratory operated by a registered medical practitioner holding a valid annual practising certificate under the Medical Act 1971. So an aesthetic clinic's transformation reel is not in the same regime as a serum brand's transformation reel, even when the two images look identical.

Most Malaysian marketers assume they are in bucket one because they sell a cream. The creative is what decides the bucket, not the product. One sentence in the caption can move you into bucket two, and the sentence is usually the one your copywriter thought was the strongest line in the ad.

Why "no approval needed" is the scariest sentence in the guideline

NPRA's FAQ on the control of cosmetics advertisement, Version 1.0, updated November 2025, puts it without hedging: in Malaysia, prior approval from a specialised board is not required for cosmetic advertisements. Instead, the system operates on the principle of self-regulation. The Cosmetic Notification Holder, the CNH, bears full responsibility to ensure that all advertisements related to their notified cosmetics comply with the relevant laws and regulations.

Read that as a transfer of risk rather than a favour. There is no reviewer to blame, no reference number to hide behind, and no moment where the state blesses your creative. The whole compliance burden lands at audit time, which is exactly when it is most expensive: the campaign has run, the spend is gone, the creative is cached across a dozen resellers' pages, and someone has complained.

The scale explains the design. Malaysia's open-data catalogue of notified cosmetic products, published on data.moh.gov.my from NPRA and Ministry of Health sources and updated daily, held 241,159 notified products from 7,476 distinct companies when counted in July 2026. Nobody is pre-vetting the advertising for a pool that size. Cosmetics here are notified, not registered or approved, under the Control of Drugs and Cosmetic Regulations 1984 promulgated under the Sale of Drugs Act 1952, following the ASEAN Cosmetic Directive procedure since 1 January 2008. A notification is valid for two years. It is a declaration you make, not a permission you receive, and the advertising rules follow the same logic.

Substantiation works the same way. Section 4.3(b) of Annex I Part 10 requires that all descriptions, claims and comparisons which relate to matters of objectively ascertainable fact should be capable of substantiation, and should be held ready for immediate production upon request by the authority. There is no filing step. There is only a folder you had better be able to open on demand. If your evidence for "visible in 14 days" is a WhatsApp thread with the factory, you do not have substantiation, you have an anecdote.

The two rules that govern the frames themselves

Section 5.2 of Annex I Part 10 is the passage every before-and-after ad in Malaysia turns on, and it is only two lines long.

First, 5.2(a): the before and after situation must reflect truthful and factual comparisons, and comparisons of the antecedent situation with the subsequent situation must not be exaggerated or misleading. This is the rule that kills the retouched after frame, the softer ring light on the second shot, the makeup that appears between them, and the model who happens to be standing straighter.

Second, 5.2(b): advertising comparing before and after situations should cite with prominence the specific time elapsed between the two situations. Two words carry the weight. Specific rules out "in just weeks". Prominence rules out 8pt grey text under the fold of the caption. If the transformation is the hero of the frame, the timeframe belongs on the frame.

The scope here is broader than most people assume, because they have internalised Meta's version. Meta attaches timeframe disclosure to a narrow allowance in the weight-loss context. NPRA attaches it to every cosmetic before-and-after comparison, full stop, with no category exception. If you take one operational rule from this page, take that one: in Malaysia, the clock goes on the creative every time.

There is a third rule that shapes the before frame in a way Meta never touches. Section 4.4(a) says advertisements should not contain any statement or illustration likely to induce fear on the part of the viewer or listener that he is suffering and without the use of the cosmetic product may worsen the condition. That is a direct constraint on how bleak your before can be, and on the voiceover that so often accompanies it. "This only gets worse if you ignore it" is a fear appeal about deterioration, and it is out.

Where the cosmetic line sits, in NPRA's own words

Section 3 of Part 10 states the prohibition in one sentence: advertisement should not refer to any medicinal claim or claim which is beyond the scope of cosmetic product. Useful, but abstract. Part 8, the claims guideline, is where it becomes operational, because NPRA published the vocabulary.

Read down the columns and the test emerges. Appearance is cosmetic. Pathology is medicinal. You may reduce the appearance of a scar. You may not remove the scar. You may reduce a dark spot. You may not treat melasma, because melasma is a diagnosis and diagnoses belong to medicine.

Two entries deserve their own warning. The mechanism-of-action row catches the copy your R&D team is proudest of: collagen production, melanin synthesis inhibition, DNA repair. These read like credibility and land as medicinal claims, because a mechanism inside the body is a pharmacological story, not a cosmetic one. And the slimming row is absolute. Slim, trim, fat loss, fat burn, inch loss and body metabolism are outside cosmetic scope in Malaysia no matter how the before-and-after is framed. Body shaping, reshape, contour and firming are the permitted vocabulary. A body transformation ad for a firming cream that says "inch loss in 4 weeks" has not made a marginal error. It has changed regime.

What happens when you cross into the Medicine Advertisements Board's territory

Cross the line and the friendly self-regulation regime disappears. Section 4B(1) of Act 290 requires Medicine Advertisements Board approval before publication of a medicinal advertisement. Section 5(1) of the same Act sets the price of ignoring it, and it applies to contraventions of sections 3, 4, 4A and 4B alike: on a first conviction, a fine not exceeding RM3,000 or imprisonment not exceeding one year or both; on a subsequent conviction, a fine not exceeding RM5,000 or imprisonment not exceeding two years or both. Those figures are low, and they are current. Act A481 raised them to these amounts with effect from 1 March 1980, the Attorney General's Chambers reprint of the Act as at 1 May 2013 still carries them, and the Chambers' amendment record for Act 290 shows nothing amending the Act after 1990.

One thing to get right if you ever cite section 5, because published summaries of it contradict each other and the reason is in the text. Section 5 does not have a single section list, it has three. The penalty in section 5(1) reaches sections 3, 4, 4A and 4B. The presumption of participation in section 5(2) and the defences in section 5(3), including the defence for publications circulating mainly among registered medical practitioners, dentists, nurses and midwives, pharmacists and licensed poisons wholesalers and retailers, reach only sections 3, 4 and 4B. Section 4A is deliberately carved out and given its own equivalents at sections 5(2A) and 5(4). Quote either list as though it were the whole of section 5 and you will be half right, which in a compliance memo is worse than useless.

Now the trapdoor most marketers never see. For the conditions in the Schedule to Act 290, approval is not merely hard to get, it is not available at all. Section 3(1) of the Act prohibits taking any part in publishing an advertisement calculated to lead to the use of an article as a medicine, an appliance or a remedy for the prevention or treatment of those conditions, and separately for their diagnosis, for the purpose of practising contraception, and for improving the condition or functioning of the human kidney or heart or improving the sexual function or sexual performance of human beings. Section 4B's approval route is then expressly limited to diseases and conditions other than those specified in section 3(1). That is the whole architecture in one line: section 3 is an outright ban, section 4B is everything else and everything else needs prior Board approval. The Schedule runs to exactly twenty items and lists cancer, diabetes, hypertension, diseases or defects of the kidney, diseases or defects of the heart, asthma, tuberculosis, leprosy, epilepsy or fits, paralysis, deafness, drug addiction, hernia or rupture, diseases of the eye, mental disorder, infertility, frigidity, impairment of sexual function or impotency, venereal disease, and nervous debility or other complaint or infirmity arising from or relating to sexual intercourse.

Note the trigger precisely, because it is easy to overstate. Section 3 of the Act does not ban every mention of diabetes in every ad. It bans the ad that positions a product as the remedy for it. The distinction matters when you are drafting, and it is where a "wellness" caption quietly turns into an offence. The section also carries a proviso for advertisements published by the Federal or a State Government, a local or public authority, the governing body of a public hospital, or a person authorised by the Minister, which is not a door a consumer brand can walk through.

So "we will just apply for approval" is not a fix for a diabetes transformation testimonial, or a device or supplement before-and-after that drifts into hypertension or a heart condition. There is no approvable version of that ad for the general public. The only compliant move is to not make the claim.

One adjacent trap, mechanically different from the Schedule and worth keeping separate in your head. Hair and scalp claims are not on the Schedule to Act 290 (nothing hair-related is), so they are not a section 3 problem. They can still fail on the cosmetic side: Part 8 lists "prevent/treat cradle cap/seborrheic dermatitis" as an unacceptable cosmetic claim. Different rulebook, different remedy, same rejected ad.

Bucket three has its own gate. Section 4A of Act 290 means a clinic's before-and-after needs Medicine Advertisements Board approval too, and eligibility for that route is restricted: the advertiser must be a private hospital, private clinic, private radiological clinic or private medical laboratory operated by a registered medical practitioner holding a valid annual practising certificate under the Medical Act 1971. The section's only other exemption runs to professional bodies of the medical or an allied profession publishing with the Minister's approval, which is not a commercial route either. A beauty centre with no registered medical practitioner is in neither category, which means a treatment-and-outcome reel from that business has no lawful route to publication in that form.

The approval the Board issues is the one you have seen stamped on other people's health ads: a KKLIU number. Our companion guide on KKLIU approval for Meta ads in Malaysia walks the submission side, the difference between a registration number and an advertising approval, and where the number sits on the creative. One point of honest uncertainty to carry into it: the display requirement and the rest of the submission mechanics are not written into Act 290 itself. Section 7(a) of the Act only empowers the Minister to make regulations that, for the purposes of sections 4A and 4B, establish the Medicine Advertisements Board, and sections 7(b) to (d) cover the manner of submission, fees, the Board's procedure and appeal to the Minister. The operational detail sits below the Act, in the Board's own regulations and its published guideline, and the Ministry host that should serve them did not respond on any attempt we made. The copy of the Board's guideline we were able to read came from a third-party mirror rather than an official gov.my page, so it belongs on a lower confidence tier than the Act text quoted above, and the commonly repeated gazette number for the establishing regulations is not something we could verify against a primary source at all. Confirm the current wording with the Board or the Pharmaceutical Services Programme rather than with a blog, this one included, before you build a launch date around it.

Who is allowed to appear beside the before-and-after

A Malaysian cosmetic before-and-after cannot be fronted by a doctor presented as one. The operative rule is older than most people assume: Section 4.1 of Annex I Part 10, "Impressions of Professional Advice or Endorsement", stamped Second Edition, August 2022, says advertisements should not carry any visual or audio presentation of individuals such as doctors, dentists or pharmacists with the impression of giving professional recommendation or endorsement, nor statements giving that impression from people presented, directly or by implication, as qualified to give it. It names the props by name: the white coat, the stethoscope, the healthcare professional environment. NPRA's November 2025 FAQ adds professional titles to the list.

Read the rule carefully, because it is narrower and stranger than the summary version that circulates. It bans the portrayal, not the person. The FAQ puts the exact question, whether a practicing or non-practicing medical professional may appear with no title, no clinical attire and no clinical setting, and answers: yes, may be considered but subject to further evaluation. A brand logo on an event backdrop behind a doctor speaking on general science draws the same conditional yes. So the dermatologist in her own clothes, in a kitchen, saying nothing about your serum, is not automatically out. She is a case-by-case call, and "subject to further evaluation" is NPRA reserving the right to disagree with you after the campaign has run.

What the FAQ does close, hard, is the sequencing trick. A medical professional speaks on general or scientific facts, and the cosmetic appears only at the end of the video, in a banner after the talk, or in the post caption: no, it is not allowed. Same answer when a host introduces the product at the end of a brand event the doctor spoke at. The cartoon workaround is shut too, though with a word most summaries drop. Animated or illustrated figures that clearly resemble medical professionals, the FAQ says, such as cartoon characters wearing white coats, stethoscopes, or labelled "doctor", may still be considered portrayals. The adverb is the whole test. A generic mascot is not a cartoon doctor. Put a stethoscope on it and it is.

Testimonials, which travel with before-and-after creative almost by default, have their own rule in Section 6 of Part 10. A testimonial or endorsement must be genuine and related to the giver's personal experience over a reasonable period of time. Obsolete testimonials, for example after a significant formulation change, shall not be used. That last clause is quietly demanding: if you reformulate, the testimonial library you built around the old formula is not reusable, and neither are the before-and-after photos it produced.

The guideline also suggests, in its own word, that an advertisement with a testimonial include the statement "The effects of the product may vary among individuals". Note that this is phrased as a suggestion, not a mandate. It is cheap to include and sensible to include, but do not tell your legal team the guideline requires it, because it does not say that.

The rules that sit around the frames, not on them

Four more provisions catch before-and-after ads sideways.

No named-competitor comparison. Section 5.1 of Part 10 says direct comparison advertisements against competitors' products or service are strictly not allowed. Comparison against an unnamed group or category may be allowed if adequately substantiated. There is no Meta equivalent to this, and it matters because before-and-after creative drifts naturally into "versus the brand you were using".

No safety reassurance. Part 8 Section 3(a)(iii) says claims about product safety should not imply, directly or indirectly, that the product is free from any side effects, and phrases such as "no side effects", "no harmful effects", and "no toxic or adverse effects" are not allowed. It also says products containing natural ingredients should not mislead consumers into assuming the product is safe because it is natural. The "gentle enough for sensitive skin, zero side effects" line that so often sits under a transformation is not a softener. It is a breach.

No borrowed authority badges. Part 8 lists as unacceptable the GMP logo or certification, "Approved by Ministry of Health (MOH)", "cosmeceutical", "mesotherapy", "injection", "micro-needling", "derma-roller", "susuk", "100% protection", and graphics referring to internal organs or substances of human origin such as Growth Factor, EGF and FGF. Non-GMP marks such as ECOCERT may be acceptable if substantiated. The trust badge you added next to the after frame to make it feel official is frequently the single most non-compliant element in the asset.

Numbers are fine if you can prove them. Part 8 Section 3(a)(iv) says numerical claims of product performance or effectiveness, such as 99.9%, in 3 days, or 10x, are acceptable if substantiated by relevant evidence. So the "7 DAYS" overlay is allowed in Malaysia. It is allowed because it is evidenced, not because it is small.

One more scoping point that ends a common argument. "It was only an Instagram story" is not a category in Malaysian law. NPRA defines advertisement as every form of advertising by the display of notices or by means of catalogues, price lists, circulars, labels, cards or other documents or materials, or by the exhibition of films or of pictures or photographs, or by means of radio or television, or in any other way including through electronic means. The definition of "advertisement" in section 2 of Act 290 is similarly broad but gets there differently. It covers any notice, circular, report, commentary, pamphlet, label, wrapper or other document, and any announcement made orally or by any means of producing or transmitting light or sound. The words internet, online, website, social media and electronic appear nowhere in that Act, which was written in 1956 and last amended in 1990. It reaches a Reel or a marketplace listing through the general words about producing or transmitting light or sound, not by naming the format, so treat anyone who tells you the Act "covers social media" as describing its effect rather than quoting its text. Paid ad, organic post, affiliate's reel, e-commerce listing, carton: same word, same rules.

Meta's layer, and the exact point where the two rulebooks disagree

Now add the second rulebook. Meta's Health and Wellness advertising standard (the live page's only changelog entry is dated 26 December 2024, and the policy was verified live in July 2026) bans side-by-side comparison after the use of a product or transformation for weight loss, with an exception for fitness classes impact such as Pilates, and bans side-by-side comparison after the use of a product or transformation for wrinkles treatment such as Botox, dermal fillers, or any other anti-aging treatment. It bans close-ups on a specific body area by pinching fat, and promotion of skin whitening or bleaching products that cause permanent skin colour change. It expressly allows, when targeted 18+, general cosmetic products, procedures and surgeries depicting before-and-after transformation, without employing negative self-perception tactics.

The instinct is to assume one rulebook contains the other. It does not. They overlap unevenly, and the differences run in both directions.

The worked example is a pigmentation serum. You build an 18+ targeted before-and-after showing clearer skin, no shaming copy, no weight loss, no wrinkle treatment. Meta's standard permits it in terms: it is a general cosmetic product depicting before-and-after transformation. Then the caption says "treats melasma in 8 weeks". NPRA's Part 8 lists treatment of melasma as unacceptable, which makes it a medicinal claim, which puts you in Act 290 territory with no Board approval in hand. The ad passed review and breached the law in the same click.

The hinge that makes this one page rather than two is that Meta has already told you this is your problem. Meta's Advertising Standards state that advertisers are responsible for understanding and complying with all applicable laws and regulations, and that failure to comply may result in a variety of consequences, including cancellation of ads and termination of your account. Compliance with Meta's standards is required in addition to all local laws, regulations and, where applicable, self-regulatory advertising codes. Approval is not a defence. Where the two differ, the stricter rule governs, every time.

A pre-publish pass for a Malaysian before-and-after

Run the asset through this in order. The first three questions decide your bucket, and the rest only apply once you know you are in bucket one.

1. Does any line name a condition as something you treat, heal, stop, remove or reverse? If yes, you are making a medicinal claim and need Medicine Advertisements Board approval before publication.
2. Is the condition on the Schedule to Act 290 (cancer, diabetes, hypertension, heart, kidney, asthma, mental disorder, infertility, impotency and the rest)? If yes, there is no approval route for a public ad. Stop.
3. Are you advertising a clinic's skill or service rather than a product? If yes, section 4A of Act 290 applies, and only a private hospital, clinic, radiological clinic or medical laboratory operated by a registered medical practitioner with a valid annual practising certificate can seek the Board's approval for it.
4. Is the elapsed time between the two states specific and prominent on the creative itself?
5. Are the two frames genuinely comparable: same lighting, same angle, same makeup, no retouching, nothing exaggerated?
6. Does the before frame avoid implying the viewer's condition will worsen without the product?
7. Does the copy use appearance language (reduce the appearance of, prevent, slow down) rather than pathology language?
8. Have you removed any slimming, fat-loss, inch-loss or metabolism vocabulary?
9. Have you removed mechanism claims (collagen production, melanin synthesis, DNA repair) and any organ or human-origin graphics?
10. Have you removed "no side effects", "safe because natural", GMP logos, and "Approved by MOH"?
11. Is anyone in the asset portrayed as a medical professional: a title, a white coat, a stethoscope, a clinical setting, or a cartoon equivalent? If a real medical professional appears with none of those, you are in "may be considered, subject to further evaluation" territory, so make sure the product is not introduced at the end or in the caption either.
12. Is each testimonial genuine, from real personal use over a reasonable period, and current for this formulation?
13. Can you produce substantiation for every factual claim and every number immediately, today, if asked?
14. Does the ad avoid naming a competitor?
15. Only now: does it clear Meta's Health and Wellness standard, 18+ targeting included?

If your team audits live creative in bulk rather than one asset at a time, the same fifteen questions work as a column header set over a spreadsheet of what you and your category are actually running. A searchable archive of Malaysian ads such as AdPlay.ai makes that sweep faster, though the discipline is what does the work, not the tooling.

One document quirk worth knowing before you cite the guideline

Two small things will confuse anyone who reads the primary sources carefully, and it is better to hear them here than to discover them mid-argument with a client.

The before-and-after rule appears twice. It sits at Section 5.2 of Annex I Part 10, and again in near-identical wording at Section 3.2 of Annex I Part 12, the Cosmetic Advertising Code. Part 10 is stamped Second Edition, August 2022. Part 12 carries no date or edition stamp anywhere in the PDF. NPRA's November 2025 FAQ names only Part 10 as the operative document. So lead on Part 10, and read Part 12 as an older code carrying the same substance rather than as a second, additional set of obligations.

Second, the FAQ that bans professional endorsement cites the rule to Part 8 Section 4.1. Section 4.1, "Impressions of Professional Advice or Endorsement", lives in Part 10, not Part 8. That is a typo in a cross-reference, not a hole in the rule, and nobody should read it as making the ban unenforceable. Note which document is which here, because the sequence gets reported backwards constantly. The endorsement ban is not a 2025 development that the FAQ introduced. It has sat in Part 10 since August 2022, white coat and stethoscope named in the text. The FAQ only interprets it, extending it to cartoon doctors and closing the sequencing workaround, and it mis-points to its own source while doing so. Treat the annex as the rule and the FAQ as the commentary, and check the annex yourself rather than trusting the pointer.

And on the 2022 dates generally: do not mistake them for staleness. NPRA's own FAQ, dated November 2025, directs Cosmetic Notification Holders to exactly these annexes, which corroborates that they are current. NPRA's 2026 circulars concern ingredient and material status, not advertising.

The short version

Malaysia does not check your before-and-after ad before it runs, and that is the point. The Cosmetic Notification Holder carries it. Keep the language on appearance rather than pathology, put a specific elapsed time prominently on the frame, keep the white coat and the MOH badge and the "no side effects" line out of the asset, and be able to open the substantiation folder the day someone asks. Cross into a medicinal claim and you are in a different regime entirely, one with prior approval, RM3,000 penalties, and twenty conditions where no approval exists.

Then run Meta's standards as a second, separate gate, and remember which failure hurts more. Meta rejects an ad. NPRA can cancel a notification, after which the product itself is illegal to sell in Malaysia. Our companion guide on before-and-after ads that pass Meta review covers the platform side in depth. This page is about the side that outlives the campaign. Where a point is finely balanced, read Annex I Parts 8 and 10 and Act 290 yourself, and ask NPRA or the Board rather than guessing.